Oncopeptides AB (publ) (LON:0RN4)

Market Cap	54.17M +61.2%
Revenue (ttm)	6.62M +108.9%
Net Income	-17.59M
EPS	n/a
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,287
Open	1.827
Previous Close	1.824
Day's Range	1.780 - 1.842
52-Week Range	1.267 - 6.505
Beta	-1.42
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydro...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 75
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RN4

Financial Performance

In 2025, Oncopeptides AB's revenue was 71.12 million, an increase of 124.72% compared to the previous year's 31.65 million. Losses were -249.59 million, -12.31% less than in 2024.

Financial numbers in SEK